Here you will find all our clinical education resources from articles to recorded webinars, all supporting equitable access to funded medicines.
The oral antiviral combination nirmatrelvir/ritonavir (Paxlovid) is funded for treating patients with COVID-19 in the community. This resource for prescribers and dispensing pharmacists links to Pharmac's access criteria (updated 1 October 2023) and to comprehensive drug interaction guidance.
The current primary care CVD management guidance strongly recommends aggressive risk management and lifestyle modification in patients with pre-existing CVD or an equivalent CVD risk. Opportunities to improve use of CVD medicines remain, particularly for Māori and Pacific peoples who lose 2.6–2.8 times more years to CVD events relative to non-Māori/non-Pacific peoples.
Looking for up-to-date information on gout or biological medicines? You can find it in our resource hubs. We’ve linked resources from multiple providers into one place so it’s easy for you to find what you need - articles, datasheets, videos, podcasts, and more.
This recorded webinar covers the introduction of the adalimumab biosimilar Amgevita in New Zealand, and what it means for primary care. Specialist Dr David Liew shares his experiences of changing patients from biologics to biosimilars in Australia, and Andrea Copeland provides some local context.
In this article, Dr Jim Vause contemplates managing CVD risk, reasons for non-adherence, inequities in CVD treatment, and how to improve communication with patients.
Adalimumab is used to treat a range of dermatological, rheumatological, gastrointestinal and ophthalmologic conditions. From 1 March, Amgevita (an adalimumab biosimilar) is funded under Special Authority. From this date, patients starting treatment with adalimumab will receive Amgevita rather than the reference product, Humira.
In this recorded webinar, Professor Lisa Stamp explores the management of gout as a long-term condition and challenges old beliefs. Dr Noni Richards introduces the EPiC Gout dashboard and outlines how it can be used to highlight and address inequities.
Looking for up-to-date information on biological medicines? You can find it here!
We’ve linked resources from multiple providers into one place so it’s easy for you to find what you need.
This article summarises the 2022 changes regarding adalimumab funding and access in New Zealand. It also provides some background and resources to foster confidence in biosimilars, and references real-world data from studies of patients changing from Humira to Amgevita.
Cardiovascular disease is the leading cause of death in New Zealand, accounting for 35 per cent of mortality in 2019. Yet it’s preventable and treatable. Māori, Pacific, and South Asian peoples have a disproportionately higher CVD risk compared with people not of these ethnicities. Therefore, CVD risk assessments in these ethnicities should begin earlier.
This guided independent reflection activity allows you to use the learning from our gout podcasts and video for continuing professional development purposes.
This video demonstrates how the three-step Ask, Build, Check health literacy model can be incorporated into discussions about the long-term management of gout, to help improve patient outcomes.
Please note that this is the video version of the Legendary Conversations podcast Episode Four: Let's talk gout (part 2).